Coherus Oncology (CHRS) Competitors

$1.42 -0.03 (-2.07%)

Closing price 04:00 PM Eastern

Extended Trading

$1.43 +0.01 (+0.92%)

As of 07:53 PM Eastern

CHRS vs. ORIC, SANA, PHAR, KURA, and ABUS

Should you buy Coherus Oncology stock or one of its competitors? MarketBeat compares Coherus Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coherus Oncology include Oric Pharmaceuticals (ORIC), Sana Biotechnology (SANA), Pharming Group (PHAR), Kura Oncology (KURA), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

How does Coherus Oncology compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Coherus Oncology has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Coherus Oncology	$42.17M	5.19	$168.02M	$1.67	0.85

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Coherus Oncology has a net margin of 397.30% compared to Oric Pharmaceuticals' net margin of 0.00%. Oric Pharmaceuticals' return on equity of -35.33% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Coherus Oncology	397.30%	-198.90%	-46.65%

Oric Pharmaceuticals presently has a consensus price target of $19.36, suggesting a potential upside of 157.15%. Coherus Oncology has a consensus price target of $8.67, suggesting a potential upside of 510.33%. Given Coherus Oncology's higher probable upside, analysts clearly believe Coherus Oncology is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 2 mentions for Oric Pharmaceuticals and 0 mentions for Coherus Oncology. Oric Pharmaceuticals' average media sentiment score of 0.00 equaled Coherus Oncology'saverage media sentiment score.

Company	Overall Sentiment
Oric Pharmaceuticals	Neutral
Coherus Oncology	Neutral

Oric Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Summary

Coherus Oncology beats Oric Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Coherus Oncology compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Coherus Oncology has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Coherus Oncology	$42.17M	5.19	$168.02M	$1.67	0.85

Coherus Oncology has a net margin of 397.30% compared to Sana Biotechnology's net margin of 0.00%. Sana Biotechnology's return on equity of -108.01% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Coherus Oncology	397.30%	-198.90%	-46.65%

In the previous week, Sana Biotechnology had 4 more articles in the media than Coherus Oncology. MarketBeat recorded 4 mentions for Sana Biotechnology and 0 mentions for Coherus Oncology. Sana Biotechnology's average media sentiment score of 0.19 beat Coherus Oncology's score of 0.00 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Sana Biotechnology	Neutral
Coherus Oncology	Neutral

Sana Biotechnology currently has a consensus price target of $9.50, suggesting a potential upside of 253.16%. Coherus Oncology has a consensus price target of $8.67, suggesting a potential upside of 510.33%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 8.1% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sana Biotechnology has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Summary

Sana Biotechnology beats Coherus Oncology on 8 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

In the previous week, Pharming Group had 3 more articles in the media than Coherus Oncology. MarketBeat recorded 3 mentions for Pharming Group and 0 mentions for Coherus Oncology. Pharming Group's average media sentiment score of 0.66 beat Coherus Oncology's score of 0.00 indicating that Pharming Group is being referred to more favorably in the media.

Company	Overall Sentiment
Pharming Group	Positive
Coherus Oncology	Neutral

Pharming Group currently has a consensus price target of $38.33, suggesting a potential upside of 199.48%. Coherus Oncology has a consensus price target of $8.67, suggesting a potential upside of 510.33%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Coherus Oncology has lower revenue, but higher earnings than Pharming Group. Coherus Oncology is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.40	$2.85M	$0.16	80.00
Coherus Oncology	$42.17M	5.19	$168.02M	$1.67	0.85

Pharming Group has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 8.1% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Coherus Oncology has a net margin of 397.30% compared to Pharming Group's net margin of 3.30%. Pharming Group's return on equity of 4.64% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Coherus Oncology	397.30%	-198.90%	-46.65%

Summary

Coherus Oncology beats Pharming Group on 9 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Kura Oncology?

Coherus Oncology (NASDAQ:CHRS) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Coherus Oncology has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

72.8% of Coherus Oncology shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Coherus Oncology presently has a consensus target price of $8.67, suggesting a potential upside of 510.33%. Kura Oncology has a consensus target price of $25.58, suggesting a potential upside of 198.87%. Given Coherus Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe Coherus Oncology is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Coherus Oncology has a net margin of 397.30% compared to Kura Oncology's net margin of -411.19%. Kura Oncology's return on equity of -141.95% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Kura Oncology	-411.19%	-141.95%	-43.28%

In the previous week, Kura Oncology had 13 more articles in the media than Coherus Oncology. MarketBeat recorded 13 mentions for Kura Oncology and 0 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.00 beat Kura Oncology's score of -0.15 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Coherus Oncology	Neutral
Kura Oncology	Neutral

Coherus Oncology has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.19	$168.02M	$1.67	0.85
Kura Oncology	$67.48M	11.26	-$278.67M	-$3.35	N/A

Summary

Coherus Oncology beats Kura Oncology on 10 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to Arbutus Biopharma?

Coherus Oncology (NASDAQ:CHRS) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Coherus Oncology has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

In the previous week, Coherus Oncology's average media sentiment score of 0.00 equaled Arbutus Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Coherus Oncology	Neutral
Arbutus Biopharma	Neutral

Coherus Oncology has a net margin of 397.30% compared to Arbutus Biopharma's net margin of 83.95%. Arbutus Biopharma's return on equity of 129.32% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Arbutus Biopharma	83.95%	129.32%	112.24%

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Coherus Oncology has higher revenue and earnings than Arbutus Biopharma. Coherus Oncology is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.19	$168.02M	$1.67	0.85
Arbutus Biopharma	$14.08M	59.49	-$33.50M	$0.83	5.11

Coherus Oncology presently has a consensus target price of $8.67, indicating a potential upside of 510.33%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential upside of 17.92%. Given Coherus Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Coherus Oncology is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Coherus Oncology beats Arbutus Biopharma on 9 of the 14 factors compared between the two stocks.

Get Coherus Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHRS vs. The Competition

Export

Metric	Coherus Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$223.66M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.58%
P/E Ratio	0.85	18.61	23.92	23.74
Price / Sales	5.19	298.40	507.55	107.95
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	2.84	8.04	10.28	6.78
Net Income	$168.02M	$23.89M	$3.57B	$337.51M
7 Day Performance	-9.55%	-5.97%	-1.43%	-2.72%
1 Month Performance	-18.86%	2.78%	3.27%	1.87%
1 Year Performance	71.08%	36.26%	23.37%	26.60%

Coherus Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHRS Coherus Oncology	2.4587 of 5 stars	$1.42 -2.1%	$8.67 +510.3%	+74.7%	$223.66M	$42.17M	0.85	330
ORIC Oric Pharmaceuticals	1.9777 of 5 stars	$8.98 +6.3%	$19.36 +115.6%	-19.5%	$929.59M	N/A	N/A	80	Analyst Forecast High Trading Volume
SANA Sana Biotechnology	3.4473 of 5 stars	$3.21 -2.7%	$9.50 +196.0%	-5.6%	$918.36M	N/A	N/A	380	Analyst Downgrade Gap Up
PHAR Pharming Group	3.8941 of 5 stars	$13.10 +0.8%	$38.33 +192.6%	+5.6%	$917.42M	$376.13M	81.88	280
KURA Kura Oncology	2.1623 of 5 stars	$9.03 -11.5%	$25.90 +186.8%	+29.9%	$905.50M	$71.64M	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CHRS) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coherus Oncology (CHRS) Competitors

CHRS vs. ORIC, SANA, PHAR, KURA, and ABUS

How does Coherus Oncology compare to Oric Pharmaceuticals?

Summary

How does Coherus Oncology compare to Sana Biotechnology?

Summary

How does Coherus Oncology compare to Pharming Group?

Summary

How does Coherus Oncology compare to Kura Oncology?

Summary

How does Coherus Oncology compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coherus Oncology (CHRS) Competitors

CHRS vs. ORIC, SANA, PHAR, KURA, and ABUS

How does Coherus Oncology compare to Oric Pharmaceuticals?

Which has higher valuation and earnings, ORIC or CHRS?

Do institutionals & insiders have more ownership in ORIC or CHRS?

Is ORIC or CHRS more profitable?

Do analysts prefer ORIC or CHRS?

Does the media prefer ORIC or CHRS?

Which has more risk & volatility, ORIC or CHRS?

Summary

How does Coherus Oncology compare to Sana Biotechnology?

Which has higher valuation and earnings, SANA or CHRS?

Is SANA or CHRS more profitable?

Does the media refer more to SANA or CHRS?

Do analysts recommend SANA or CHRS?

Do insiders & institutionals hold more shares of SANA or CHRS?

Which has more volatility and risk, SANA or CHRS?

Summary

How does Coherus Oncology compare to Pharming Group?

Does the media refer more to PHAR or CHRS?

Do analysts recommend PHAR or CHRS?

Which has higher valuation and earnings, PHAR or CHRS?

Which has more volatility and risk, PHAR or CHRS?

Do insiders & institutionals hold more shares of PHAR or CHRS?

Is PHAR or CHRS more profitable?

Summary

How does Coherus Oncology compare to Kura Oncology?

Which has more risk & volatility, CHRS or KURA?

Do institutionals & insiders have more ownership in CHRS or KURA?

Do analysts prefer CHRS or KURA?

Is CHRS or KURA more profitable?

Does the media prefer CHRS or KURA?

Which has higher earnings and valuation, CHRS or KURA?

Summary

How does Coherus Oncology compare to Arbutus Biopharma?

Which has more volatility and risk, CHRS or ABUS?

Does the media favor CHRS or ABUS?

Is CHRS or ABUS more profitable?

Do insiders & institutionals believe in CHRS or ABUS?

Which has preferable valuation and earnings, CHRS or ABUS?

Do analysts recommend CHRS or ABUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools